773 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
AMGN Amgen Inc. $200.81 $129.98B N/A
Article Searches
5 Major Drug Stocks Likely to Beat Q1 Earnings Estimates http://www.zacks.com/stock/news/256560/5-major-drug-stocks-likely-to-beat-q1-earnings-estimates?cid=CS-ZC-FT-256560 Apr 17, 2017 - 2017 is expected to be a strong year for drug stocks.
AbbVie Inc.: The Bear Case From a Bull https://www.fool.com/investing/2017/04/14/abbvie-inc-the-bear-case-from-a-bull.aspx?source=iedfolrf0000001 Apr 14, 2017 - AbbVie has a lot of things going for it, but the biotech faces some major risks.
Mylan Down on FDA Warning Letter to Manufacturing Facility http://www.zacks.com/stock/news/256244/mylan-down-on-fda-warning-letter-to-manufacturing-facility?cid=CS-ZC-FT-256244 Apr 12, 2017 - Shares of Mylan, Inc. (MYL) dropped 2% after the company received a warning letter from the FDA for its manufacturing facility in India
ANTH's (ANTH) Blisibimod Completes Dosing in Phase III Study http://www.zacks.com/stock/news/256054/anths-anth-blisibimod-completes-dosing-in-phase-iii-study?cid=CS-ZC-FT-256054 Apr 11, 2017 - Anthera Pharmaceuticals, Inc. (ANTH) recently announced the completion of dosing in a phase II study, BRIGHT-SC. The study evaluated key pipeline candidate blisibimod for treatment of patients with IgA nephropathy (IgAN).
Kite Pharma Completes Filing for CAR-T Therapy with FDA http://www.zacks.com/stock/news/254949/kite-pharma-completes-filing-for-car-t-therapy-with-fda?cid=CS-ZC-FT-254949 Apr 03, 2017 - Kite Pharma, Inc. (KITE) announced that it has completed the filing of a rolling submission of the Biologics License Application (BLA) for its lead pipeline candidate, axicabtagene ciloleucel to the FDA.
Mylan Receives CRL for Generic Advair Diskus From the FDA http://www.zacks.com/stock/news/254929/mylan-receives-crl-for-generic-advair-diskus-from-the-fda?cid=CS-ZC-FT-254929 Mar 31, 2017 - Mylan N.V. (MYL) recently suffered a huge setback when it received a complete response letter from the FDA regarding its ANDA for the generic version of asthma drug Advair Diskus.
Amgen's Leukemia Drug Accepted for Priority Review by FDA http://www.zacks.com/stock/news/254704/amgens-leukemia-drug-accepted-for-priority-review-by-fda?cid=CS-ZC-FT-254704 Mar 30, 2017 - Amgen Inc. (AMGN) recently announced that its supplemental biologics license application (sBLA) for its leukemia immunotherapy, Blincyto, has been accepted for priority review by the FDA.
Biotech Stock Roundup: Regeneron, Tesaro Drugs Approved, Vertex Scores Big in Study http://www.zacks.com/stock/news/254462/biotech-stock-roundup-regeneron-tesaro-drugs-approved-vertex-scores-big-in-study?cid=CS-ZC-FT-254462 Mar 29, 2017 - Key updates this week include the FDA approval of Tesaro's (TSRO) PARP inhibitor and Regeneron's eczema drug.
Pfizer's Arthritis Drug Xeljanz Gets Marketing Nod in Europe http://www.zacks.com/stock/news/254398/pfizers-arthritis-drug-xeljanz-gets-marketing-nod-in-europe?cid=CS-ZC-FT-254398 Mar 28, 2017 - Pfizer, Inc.'s (PFE) rheumatoid arthritis (RA) drug, Xeljanz has received marketing approval in Europe.
The 'Fearless Girl' Statue Isn't a Symbol, It Is an Advertisement http://www.zacks.com/stock/news/254260/the-fearless-girl-statue-isnt-a-symbol-it-is-an-advertisement?cid=CS-ZC-FT-254260 Mar 28, 2017 - The Fearless Girl statue has taken New York City by storm. However, this statue, which is facing down the Charging Bull, is actually an ad.

Pages: 1...6364656667686970717273...78

<<<Page 68>